ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
response rate and a 76% complete response rate, with 56% of patients remaining progression-free after 24 months. These results are comparable to those of existing treatments Carvykti and Abecma, but Anito-cel's safety profile may be more favorable, with no reported neurotoxicity. Despite this, Arcellx faces challenges in competing with established treatments, and has partnered with Gilead to help with marketing and FDA approval. Analysts predict Anito-cel's global sales will reach $505m by 2030, compared to $9.8bn for Carvykti and $853m for Abecma. At the American Society of Hematology (ASH) Annual Meeting on 9 December, Arcellx published Phase II results of the IMMagine-1 trial for its BCMA-targeting autologous cell therapy, anitocabtagene autoleucel (Anito-cel) in patients with relapsed or refractory multiple myeloma (r/r MM) who have received at least three prior regimens, including a proteasome inhibitor, an immunomodulatory drug, and an anti-cluster of differentiation 38 antibo
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at UBS Group AG from $106.00 to $114.00. They now have a "buy" rating on the stock.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.MarketBeat
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and ExpositionBusiness Wire
ACLX
Earnings
- 11/7/24 - Beat
ACLX
Sec Filings
- 12/12/24 - Form 8-K
- 12/9/24 - Form 8-K
- 12/5/24 - Form 4
- ACLX's page on the SEC website